๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study

โœ Scribed by Brad S. Kahl; Nancy L. Bartlett; John P. Leonard; Ling Chen; Kristen Ganjoo; Michael E. Williams; Myron S. Czuczman; K. Sue Robinson; Robin Joyce; Richard H. van der Jagt; Bruce D. Cheson

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
186 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Durable complete responses from therapy
Durable complete responses from therapy with combined epratuzumab and rituximab : Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma
โœ John P. Leonard; Stephen J. Schuster; Christos Emmanouilides; Felix Couture; Nic ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 134 KB

## Abstract ## BACKGROUND. In this international, multicenter trial, the authors evaluated rituximab (antiโ€CD20) plus epratuzumab (antiโ€CD22) in patients with postchemotherapy relapsed/refractory, indolent nonโ€Hodgkin lymphoma (NHL), including longโ€term efficacy. ## METHODS. Fortyโ€nine patients